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The X-linked lymphoproliferative syndrome (XLP) is a rare, inherited immunodeﬁciency characterized by recurrent episodes of
hemophagocytic lymphohistiocytosis, hypogammaglobulinemia, and/or lymphomas. Recently, X-linked inhibitor of apoptosis
(XIAP/BIRC4) gene defects, in families with XLP but without SH2D1A gene defects, has been deﬁned. The distinction from
primary immunodeﬁciencies with a deﬁned genetic cause is mandatory. A six-year-old male patient was admitted with the
complaints of persistent general lymphadenopathy, for two years had fever, bilateral cervical multiple microlymphadenopathy,
hepatic/splenic enlargement with laboratory ﬁndings as decreased serum immunoglobulins, negative EBV VCA IgM (viral capsid
antigen) and anti-EBV EA (antibody to early D antigen), positive EBV VCA IgG (viral capsid antigen) and EBV EBNA (antibody
to nuclear antigen). SH2D1A gene analysis was negative. XIAP/BIRC4 sequencing revealed two novel single nucleotide variants
(exon 7, 1978G > A, and 1996T > A) in the 3 UTR of the gene in both patient and mother which were not disease causing. XIAP
proteinexpressionwasfoundtobe normal.Theclinicalandlaboratoryresemblance,nogenemutations,andnormalXIAPprotein
expression led us to think that there may be another responsible gene for XLP. The patient will to be followed up as CVID until he
presents new diagnostic signs or until the identiﬁcation of a new gene.
1.Introduction
The X-linked lymphoproliferative syndrome (XLP) is a rare,
inherited immunodeﬁciency characterized by recurrent
episodes of hemophagocytic lymphohistiocytosis (HLH),
hypogammaglobulinemia, and/or lymphomas [1]. It is
exceptional among human X-linked immunodeﬁciencies as
critical events occur after EBV infection. However, detailed
analyses ofthe aﬀected individuals revealed that the immune
defect was broader than the impaired control of EBV infec-
tion[2].Normally,primary EBVinfectioncanoccurwithout
characteristic symptoms, or it can elicit mononucleosis of
variableseverity,butitregularly subsides.Onthecontrary,in
the XLP patients, mononucleosis can be fatal with explosive
activation and proliferation of cellular components of the
immune system. The life threatening immunological defect
is thus characterized by the defect of protection against the
proliferation of EBV-transformed B cells [2–4].
Mutations in the signalling lymphocyte activation
molecule- (SLAM-) associated protein SAP are responsible
for 60–80% of cases of familial XLP [1, 4–6]. The gene
defective in XLP has been identiﬁed at Xq25 and has been
deﬁned as SH2D1A. Mutation analyses of the gene are
currently required for a deﬁnitive diagnosis of XLP [6].
Recently, mutations in the X-linked inhibitor of apoptosis
(XIAP/BIRC4) gene, in families with XLP but without SAP
mutation, have been deﬁned [1, 7]. Zhu et al. evaluated 42
patients having XLP and identiﬁed XIAP deﬁciency at 2.4%
of them [8].
X-linked inhibitor of apoptosis protein (XIAP) has
originally been described as an antiapoptotic protein that
acts through direct inhibition of caspases. It is ubiquitously
expressed in all normal tissues [9–11]. However, XIAP2 Case Reports in Medicine
is also involved in a number of signaling pathways, for
example, in nuclear factor kB, transforming growth factor,
and bone morphogenetic protein signaling pathways [4, 7,
8]. Polymorphisms in the XIAP/BIRC4 gene may inﬂuence
XIAP production and activity [12]. In addition, loss of
function due to nonsense mutations in the XIAP gene have
been observed in patients with XLP [1, 7, 8, 13].
Common variable immunodeﬁciency (CVID) is the
most prevalent symptomatic primary immunodeﬁciency
in humans [13]. Despite the discovery of genetic defects
in ICOS, TNFRSF13b/TACI, and CD19, which prove that
defects in single genes can be associated with a CVID phe-
notype, the diagnosis of CVID remains as clinical diagnosis
of exclusion in most patients [13]. CVID patients may also
have susceptibility to malignancy, especially lymphomas [14,
15]. Several genetically deﬁned primary immunodeﬁciencies
including XLP may mimic CVID.
Based on the previous reports that XLP and CVID may
mimic each other, we report a 6-year-old boy, who has the
clinical and laboratory signs of both disease. We revealed the
diﬃculty of having an exact diagnosis although molecular
analysis for XLP was performed.
2.CasePresentation
A six-year-old male patient, second child of nonconsan-
guineous healthy parents, was admitted to hospital with
complaints of persistent general lymphadenopathy, espe-
cially at the cervical region, for the last two years. He
had one healthy brother. On admission, he was four years
old, and his weight was 15kg (25th percentile) while his
height was 112cm (50–75th percentile). Clinical ﬁndings
were fever, pallor, ragades on lips, bilateral cervical multiple
microlymphadenopathy, grade 2-3 hypertrophic tonsils and
pharyngeal hyperemia, and hepatic and splenic enlargement.
The laboratory results were as follows: white blood
cell count 14.600/mm3 with 26% polymorphonucle-
ar cells, 70% lymphocytes, 4% monocytes on peripher-
al smear. Acute phase reactants such as CRP concentrations
(C reactive protein) and erythrocyte sedimentation rate
(ESR) were normal. On admission, he had mildly decreased
serum IgG while IgA and IgM concentrations showed
normal levels (IgG 694mg/dL, IgM 84.7mg/dL, IgA
39mg/dL) [16]. However, during follow-up of one year,
immunoglobulins decreased continuously (pre-IVIG-IgG:
578–495–342mg/dL, IgM:72–64–32mg/dL, IgA: 37–32–
29mg/dL). Speciﬁc antibody responses (IgG) against tetanus
(80mIU/mL) and haemophilus inﬂuenza type B (<1μg/mL)
were inadequate.
Lymphocyte subset analysis revealed the percentages
of lymphocytes bearing CD3+; 51%, CD19+; 37%,
CD3+CD4+; 17%, CD3+CD8+; 27%, CD19+CD40+; 37%,
CD40L; 75%, CD16+CD56+CD3+ NKT (natural killer T
cells); 1.8% (183/mm3)a n dC D 3 −CD56+; 8%. Serological
investigations for CMV (Cytomegalovirus), HIV (Human
Immunodeﬁciency Virus), HBV (Hepatitis B virus), HSV
(Herpes Simplex virus), Parvovirus, and culture for acid
fast bacilli and toxoplasma serology were negative. EBV
VCA IgM was negative, and IgG was positive. Paraaortic
multiple lymphadenomegalies were shown by abdominal
ultrasonography. Direct Coombs test and antinuclear
antibody were negative (Table 1).
In addition to low IgG and normal IgM, class switch
recombination test (Dr. Anne Durandy’s lab, Necker, Paris,
France) was found to be absent, and this ﬁnding raised
the suspicion of possible hyper-IgM syndrome (class switch
recombination defects) in the ﬁrst six months of follow-
up. After an episode of fever accompanied by generalized
lymphadenopathy, it was found out that he was antiEBV
VCA and antiEBV EBNA positive and no EBV EA antibodies
were measured. He was positive for EBV DNA on two biop-
sies from cervical and intraabdominal lymph nodes. Bone
marrow examination ruled out myelodysplastic syndrome,
lymphohistiocytosis, andlymphoma.Whenitwas conﬁrmed
that he had persistent EBV infection accompanied by mild
hypogammaglobulinemia, possibility of XLP was searched
out.
Initial screening for a mutation in the SH2D1A gene was
carried out,and no gene defect was identiﬁed. Consequently,
XIAP/BIRC4 gene was investigated. Sequence analysis was
carried out on genomic DNA extracted from EDTA anti-
coagulated venous blood using QiAamp DNA Blood Mini
Kit (QIAGEN GmbH, Hilden Germany) according to the
manufacturer’s instructions. All7 exonsof XIAP/BIRC4 gene
were ampliﬁed by polymerase chain reaction (PCR) using
ﬂanking intronic primers. PCR amplicons were sequencedin
both directions with an ABI 3100 automatic DNAsequencer.
Before sequencing, the PCR products were puriﬁed using
Exo-SAP PCR puriﬁcation Kit (Amersham Life Sciences).
Seven exons of XIAP/BIRC4 gene were searched out, and
a heterozygous 1978G > A and 1996T > A nucleotide sub-
stitution in region of 3 UTR in exon 7 was detected. Defect
in this region of XIAP/BIRC4 gene has not been reported
elsewhere including INFEVERS database. The same ﬁnding
wasfoundinthemotherwhilefatherandelderbrotherofthe
patient were normal for XIAP/BIRC4 sequencing (Table 2).
Then, the samples of the patient were sent to a European
center experienced in research of XLP patients, and XIAP
protein expression was examined by Western Blot method
[1]. Expression of XIAP was found to be normal in the lysate
of peripheric blood lymphocytes of the patient.
On the third year of his follow-up in out-patient clinic,
he developed multiple enlarged intraabdominal lymphade-
nomegaly and admitted to Pediatric Emergency Department
with the diagnosis of invagination of intestines. After
operation, in biopsy specimens, EBV-positive non-Hodgkin
lymphoma (Burkitt) was observed (stage III and risk
group II). Methotrexate, vincristine, cytarabine, etoposide,
and intrathecally methotrexate, arabinoside-C combined
therapies were applied and recovered in four months. Now,
he is on regular intravenous immunoglobulin treatment and
stillinfollow-upinpediatricimmunologyout-patientclinic.
3.Discussion
Diagnosis of XLP is complicated because of its clinical
heterogeneity and rare incidence, particularly in malesCase Reports in Medicine 3
Table 1: Laboratory ﬁndings of patient.
Patient Normal values for his age
IgG (mg/dL) 694 986.2 ±209.6
IgM (mg/dL) 84.7 105.8 ± 40.8
IgA (mg/dL) 39 91.9 ±37.4
WBC/mm3 14600 (26% pnl, 70% lym, 4% mono) 4000–10400
Absolute lymphocyte counts/mm3 10220 1500–5200
CD3+ (%-absolute count) 51–5212 55–79/1900–3600
CD19+ (%-absolute count) 37–3781 11–31/300–1200
CD3+CD4+ (%-absolute count) 17–1737 26–49 / 600–2000
CD3+CD8+ (%-absolute count) 27–2759 9–35/300–1300
CD19+CD40+ (%-absolute count) 37–3781 Expressed on all B lymphocytes
CD40L+ on activated T cells (%) 75 50 (24 hours after stimulation)
CD3−CD56+CD16+ (NK) (%-absolute count) 8–817 4–26/90–900
CD3−CD56+CD16+ (NKT) (%-absolute count) 1.8 >4
Anti-nuclear antikor Negative Negative
Direct Coombs Negative Negative
AntiEBV VCA (IgM) Negative Negative
AntiEBV VCA (IgG) Positive Negative
AntiEBV EBNA (IgG) Positive Negative
EBV anti-EA Negative Negative
EBV DNA Positive (lymph node biopsy) Negative
Table 2: Molecular analysis of SH2D1A and XIAP/BIRC4 genes in patient and family members.
Patient Father Mother Brother
SH2D1A N N N N
XIAP/BIRC4
Heterozygous 1978 G > A and 1996 T > A
nucleotide substitution in 3 UTR region
of exon7
N
Heterozygous 1978 G > A and 1996 T > A
nucleotide substitution in 3 UTR region
of exon 7
N
manifesting with a phenotype consistent with XLP but
without a family history. Lymphadenopathy, splenic and/or
liver enlargement, fever, dysglammagobulinemia, anemia,
and thrombocytopenia are also common features of various
immunodeﬁciencies, including CVID.
Clinical and laboratory ﬁndings of our patient were
similar to previous XLP reports [1, 7, 13]. All patients,
in these series had splenic enlargement. In Salzer et al.
series [13], lymph node enlargement was reported in 55%
of patients and hypogammaglobulinemia was reported in
all of patients as in our case. Rigaud et al. [1]r e p o r t e d
hypogammaglobulinemia in only three patients out of 12.
T h e yr e p o r t e dH L Hi n1 1o f1 2p a t i e n t s ,b u ti no u rc a s ea n d
also in other two series, HLH was not present [1, 7, 13].
There was a proven EBV infection in our patient. The
presence of EBV infection was 75% in Rigaud et al. [1]
and 22% in Salzer et al. [13] reports, respectively. Although
colitis was the prominent symptom in Rigaud et al. [1]a n d
Salzer et al. [13] series, it was absent in our and Doshi et
al. cases. Rigaud et al. [1] reported the mean age of the
patients as six years. Salzer et al. examined sequence analysis
of BIRC4/XIAP genes in male patients who were previously
diagnosed as CVID; therefore, the mean age of these patients
reported in this study was 32 years [13].
NKT cells are a unique population of T cells that express
an invariant T cell receptor which recognizes glycosphin-
golipid antigens presented by the CD1d molecule. These
cells are known to be absent in patients with XLP due to
SAP gene defect [4]. XIAP-deﬁcient patients also show no
T, B, or NK cell lymphopenia, but very low numbers of
NKT cell [1, 4]. Rigaud et al. [1] thought that NKT cells
might be particularly sensitive to apoptosis, and XIAP might
be required for their survival and/or development [1]. In
contrast,Marshetal.[17]concludedthatinvariant NKTcells
(iNKT) (deﬁned as CD3 lymphocytes bearing an invariant
TcR Vα14 Vβ11) were not decreased in the majority of
XIAP-deﬁcient patients. In our patient, the percentages of
total T and NK cells are normal. B cells and CD8+ cells
were slightly elevated, probably because of recurrent and
chronic infections. NKT cell percentage (deﬁned by the
coexpression of CD3 and CD16/CD56) was found to be
low by ﬂow cytometric analyses compared to age-matched
reference values of healthy children [18–21].
The clinical and some laboratory signs were good
evidences to diagnose XLP. However, SH2D1A gene was
normal, and the ﬁnding in 3 UTR region of seventh exon
of XIAP/BIRC4 gene was not thought to be disease causing,
becauseofreported publicdatabases.Inthepreviousreports,4 Case Reports in Medicine
Salzer et al. [13] pointed out that these 3 UTR nucleotide
changes are polymorphisms. In addition, the mother who
had the same amino acid changes was very healthy. Normal
expression of XIAP protein conﬁrmed our suggestions.
Furthermore, it is very unlikely that XIAP is involved in the
pathology of this patient as no association with lymphoma
has been reported yet [22]. The clinical and laboratory
resemblance and the ﬁndings of no gene mutation and
normal XIAP protein expression led us to think that there
may be another responsible gene for XLP.
Le Guern et al. [23] described two CVID cases who
developed B cell lymphomas, one related to EBV infection,
5 and 12 years after CVID had been diagnosed. Polizzotto et
al. [24] reported a case of Burkitt lymphoma in the setting of
CVID. Because of the occurrence of lymphomas during the
course of CVID, the other diagnosis for our patient is still
CVID. This patient also fulﬁlls the criteria for CVID [25]. He
will be followed up and managed as CVID until he presents
new signs or until the identiﬁcation of a new gene.
In conclusion,thediﬀerentialdiagnosis is notalways easy
betweenXLPandCVIDpatients.Molecularanalysisforwell-
known mutatedgenesofXLP may notsolve the problemand
the patients have to be carefully long-term monitored and
treated for life-threatening complications.
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